<PAGE>

                                   FORM 10-QSB

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20429


(Mark One)
[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2003

[ ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
         THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________  to ___________________

Commission File Number     0-27227    .
                      ----------------

                          ALLERGY RESEARCH GROUP, INC.
             (Exact name of registrant as specified in its charter)


            Florida                                          13-3940486
-------------------------------                          -------------------
(State or other jurisdiction of                             (IRS Employer
 incorporation or organization)                          Identification No.)


                 30806 Santana Street, Hayward, California 94544

                    (Address of principal executive offices)

(Issuer's telephone number) (800) 545-9960.
                            --------------


--------------------------------------------------------------------------------
              (Former name, former address and former fiscal year,
                         if changed since last report)

Checkmark whether the issuer (1) has filed all reports required to be filed by
Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [ X ]  No [   ]

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: 14,722,105 shares of Issuer's voting
common stock were outstanding on July 31, 2003.

<PAGE>

                          ALLERGY RESEARCH GROUP, INC.
                            INDEX TO QUARTERLY REPORT
                                 ON FORM 10-QSB

PART I. FINANCIAL INFORMATION                                               PAGE

     ITEM 1. Condensed Consolidated Financial Statements (Unaudited):

          Consolidated Balance Sheets........................................  2

          Consolidated Income Statements.....................................  3

          Consolidated Statements of Cash Flows..............................  4

          Notes to Condensed Consolidated Financial Statements...............  5

     ITEM 2. Management's Discussion and Analysis............................  7

     ITEM 3. Controls and Procedures......................................... 14

PART II. OTHER INFORMATION

     ITEM 1. Legal Proceedings............................................... 14
     ITEM 2. Changes in Securities and Use of Proceeds....................... 14
     ITEM 3. Defaults Upon Senior Securities................................. 14
     ITEM 4. Submission of Matters to a Vote of Security Holders............. 14
     ITEM 5. Other Information............................................... 14
     ITEM 6. Exhibits and Reports on Form 8-K................................ 15



SIGNATURE.................................................................... 16


                                       1
<PAGE>

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

In the opinion of management, the accompanying unaudited financial statements
included in this Form 10-QSB reflect all adjustments (consisting only of normal
recurring accruals) necessary for a fair presentation of the results of
operations for the periods presented. The results of operations for the periods
presented are not necessarily indicative of the results to be expected for the
full year.

<TABLE>

                               ALLERGY RESEARCH GROUP, INC.
                                CONSOLIDATED BALANCE SHEET
<CAPTION>
                                                                                 June 30,
                                                                                   2003
                                                                                -----------
                                                                                (unaudited)
<S>                                                                             <C>
ASSETS
Current Assets
    Cash & Cash Equivalents                                                     $   956,055
    Accounts Receivable, Net of Allowance for Doubtful Accounts of $53,884          750,086
    Inventories                                                                   1,543,083
    Prepaid Expenses and Other Current Assets                                       234,608
    Deferred Tax Asset                                                              404,085
                                                                                ------------
Total Current Assets                                                              3,887,917

Property and Equipment, Net                                                         257,510

Other Assets
    Deposits                                                                         29,730
    Due From Officer                                                                 69,562
    Intangible Assets, Net of Amortization of  $21,384                               20,179
                                                                                ------------
Total Other Assets                                                                  119,471
                                                                                ------------

Total Assets                                                                    $ 4,264,898
                                                                                ============

LIABILITIES AND STOCKHOLDERS EQUITY
Current Liabilities
    Accounts Payable                                                            $   647,117
    Accrued Liabilities                                                             233,163
    Capital Lease Obligation, Current Portion                                        14,854
    Income Taxes Payable                                                             53,997
                                                                                ------------
Total Current Liabilities                                                           949,131

Stockholders' Equity
    Preferred Stock, $.25 Par Value, Authorized 1,000,000
       Shares, Issued and Outstanding                                                  None
    Common Stock, $.001 Par Value, Authorized 100,000,000 Shares
      Issued: 15,105,355 Outstanding:14,722,105                                      15,105
    Additional Paid In Capital                                                    1,141,377
    Retained Earnings                                                             2,240,858
    Less: Treasury Stock, at cost                                                   (81,573)
                                                                                ------------
Total Stockholders' Equity                                                        3,315,767
                                                                                ------------
Total Liabilities and Stockholders' Equity                                      $ 4,264,898
                                                                                ============
</TABLE>
                                       2

See Notes to Condensed Consolidated Financial Statements.

<PAGE>
<TABLE>

                                               ALLERGY RESEARCH GROUP, INC.
                                              CONSOLIDATED INCOME STATEMENTS
                                                       (UNAUDITED)
<CAPTION>

                                                        Three Months Ended                     Six Months Ended
                                                             June 30,                              June 30,
                                                             --------                              --------
                                                      2003              2002               2003                2002
                                                      ----              ----               ----                ----
<S>                                              <C>                <C>                <C>                <C>
Revenues                                         $  3,447,130       $  3,234,125       $  6,895,892       $  6,240,312
Cost of Sales                                       1,990,480          2,034,133          3,945,320          3,833,343
                                                 -------------      -------------      -------------      -------------
Gross Profit                                        1,456,650          1,199,992          2,950,572          2,406,969

Operating Expenses
        Selling, General and Administrative           947,582            920,085          1,839,769          1,817,033
        Research and Development                       42,499             48,299             94,624             92,169
                                                 -------------      -------------      -------------      -------------
Operating Expenses                                    990,081            968,384          1,934,393          1,909,202
                                                 -------------      -------------      -------------      -------------

Operating Income                                      466,569            231,608          1,016,179            497,767

Other Income (Expense)
        Interest Expense                                 (375)            (9,936)            (1,095)           (21,917)
        Interest Income                                 2,705                821              4,788              3,598
                                                 -------------      -------------      -------------      -------------
Other Income (Expense)                                  2,330             (9,115)             3,693            (18,319)

Net Income                                            468,899            222,493          1,019,872            479,448

Provision (Benefit) for Income Taxes                   41,451                800             90,157            (35,200)
                                                 -------------      -------------      -------------      -------------

Net Income Available to Common Shareholders      $    427,448       $    221,693       $    929,715       $    514,648
                                                 =============      =============      =============      =============


Weighted Average Common Shares Outstanding         14,722,105         15,096,784         14,722,105         15,101,021

Basic and Diluted Earnings Per Share             $       0.03       $       0.01       $       0.06       $       0.03
                                                 =============      =============      =============      =============
</TABLE>

See Notes to Condensed Consolidated Financial Statements.

                                                                3
<PAGE>
<TABLE>

                                              ALLERGY RESEARCH GROUP, INC.
                                           CONSOLIDATED STATEMENT OF CASH FLOW
                                                       (Unaudited)
<CAPTION>

                                                                                                Six Months Ended
                                                                                                    June 30,
                                                                                              2003            2002
                                                                                              ----            ----
<S>                                                                                        <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
     Net Income                                                                            $ 929,715       $ 514,648
                                                                                           ----------      ----------
     Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities
          Depreciation and Amortization                                                       83,592         110,311
          Due From Officer Adjustment                                                         10,000
     Changes in Assets and Liabilities
          (Increase) Decrease in Accounts Receivable                                        (158,529)       (226,250)
          (Increase) Decrease in Inventory                                                    58,536         103,704
          (Increase) Decrease in Prepaid Expenses and Other Assets                          (115,799)         13,622
          (Increase) Decrease in Deferred Tax Assets                                              --         (36,000)
          Increase (Decrease) in Accounts Payable and Accrued Liabilities                   (183,551)       (101,858)
          Increase (Decrease) in Income Taxes Payable                                        (16,718)           (862)
                                                                                           ----------      ----------
     Total Adjustments                                                                      (332,469)       (127,333)
                                                                                           ----------      ----------
Net Cash Provided By Operating Activities                                                    597,246         387,315

Net Cash Flows From Investing Activities
      Acquisition of Property and Equipment                                                   (5,405)        (12,121)
      Repayments From (Advances To) Officers                                                  58,129          (3,572)
                                                                                           ----------      ----------
Net Cash Flows Provided By (Used In) Investing Activities                                     52,724         (15,693)

Cash Flows From Financing Activities
     Purchase of Treasury Shares                                                                  --         (14,300)
     Repayment on Notes Payable                                                                   --        (302,962)
     Repayment on Capital Lease Obligations                                                  (33,917)        (26,797)
                                                                                           ----------      ----------
Net Cash Used In Financing Activities                                                        (33,917)       (344,059)
                                                                                           ----------      ----------


Increase (Decrease) in Cash and Cash Equivalents                                             616,053          27,563
Cash and Cash Equivalents, Beginning of Period                                               340,002         199,499
                                                                                           ----------      ----------
Cash and Cash Equivalents, End of Period                                                   $ 956,055       $ 227,062
                                                                                           ==========      ==========

See Notes to Condensed Consolidated Financial Statements.
</TABLE>

                                                           4
<PAGE>

                          ALLERGY RESEARCH GROUP, INC.
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
                                  JUNE 30, 2003
                                   (UNAUDITED)

Note 1 - Statement of Information Furnished
-------------------------------------------

         The accompanying unaudited Consolidated Financial Statements of Allergy
         Research Group, Inc. ("the Company") have been prepared in accordance
         with generally accepted accounting principles in the United States of
         America for interim financial information and the instructions to Form
         10-QSB. Accordingly, they do not include all the information and
         footnotes required by generally accepted accounting principles for
         complete financial statements. In the opinion of management, all
         adjustments (which include only normal recurring adjustments) necessary
         to present fairly the financial position, results of operations and
         cash flows for all periods presented have been made. Preparing
         financial statements requires management to make estimates and
         assumptions that affect the reported amounts of assets, liabilities,
         revenue and expenses. Examples include provisions for returns,
         accounting for income taxes, bad debts, and length of product life
         cycles and property, plant and equipment lives for depreciation
         purposes. Actual results may differ from these estimates. The results
         of operations for the six-month period ended June 30, 2003 are not
         necessarily indicative of the operating results that may be expected
         for the entire year ending December 31, 2003. These financial
         statements should be read in conjunction with the Management's
         Discussion and Analysis and financial statements and notes thereto as
         of and for the year ended December 31, 2002, filed with the Company's
         Annual Report on Form 10-KSB on March 31, 2003.

         Certain accounts from prior years have been reclassified to conform to
         the current year's presentation. These changes had no effect on
         previously reported results of operations or total stockholders'
         equity.

Note 2 - Earnings Per Share
---------------------------

         Basic earnings per share is based on the weighted average number of
         common shares outstanding. Diluted earnings or loss per share is based
         on the weighted average number of common shares outstanding and
         dilutive common stock equivalents. All earnings per share amounts in
         these financial statements are basic earnings per share as defined by
         SFAS No. 128, "Earnings Per Share." Diluted weighted average shares
         outstanding exclude the potential common shares from options because to
         do so would be antidilutive.

          The computation of basic and diluted earnings per share is as follows:

<TABLE>
<CAPTION>
                                                  Three Months   Three Months     Six Months     Six Months
                                                     Ended          Ended           Ended          Ended
                                                    6/30/03        6/30/02         6/30/03        6/30/02
                                                    -------        -------         -------        -------
<S>                                                 <C>            <C>             <C>            <C>
         Numerator-Net Income Available
         to Common Stockholders                     $  427,448     $  221,693      $  929,715     $  514,648
                                                    ==========     ==========      ==========     ==========

         Denominator-Weighted Average Number
         of Common Shares Outstanding               14,722,105     15,096,784      14,722,105     15,101,021
                                                    ==========     ==========      ==========     ==========

         Basic and Diluted Earnings Per Common
         Share                                       $    0.03      $    0.01        $   0.06       $   0.03
                                                    ==========     ==========      ==========     ==========
</TABLE>

                                                      5
<PAGE>

Note 3 - Line of Credit
-----------------------

         On August 19, 2002, a Merrill Lynch Working Capital Management Account
         (WCMA) was activated. The WCMA replaced the line of credit with City
         National Bank and provides for a line of credit up to $500,000 for
         twelve months bearing interest at the London Interbank Offered Rate
         (LIBOR) plus 3.15%. The LIBOR plus 3.15% at June 30, 2003 was 4.27%.
         Interest is due monthly; however, the balance due on the line of credit
         was zero throughout the entire first half of 2003. The note is secured
         by substantially all of the assets of the Company and is personally
         guaranteed by the officers of the Company. The WCMA account immediately
         pays down the line of credit when deposits are received. When checks
         are issued, the line of credit is utilized if no cash is available. If
         the line of credit has a zero balance, the WCMA account pays interest
         on deposits at Merrill Lynch's money market rate which as of June 30,
         2003 was .78%.


Note 4 - Stockholders' Equity and Subsequent Events
---------------------------------------------------

         On May 3, 2002, the Company announced a stock repurchase plan, whereby
         the Company may repurchase between 1,000,000 and 2,500,000 shares of
         the Company's common stock in open market transactions, from time to
         time during the next two years in compliance with Rule 10b-18 of the
         Securities Exchange Act of 1934 and all other applicable securities
         regulations. Repurchases of common shares in the open market will
         provide shares for issuance to employees under stock option and stock
         purchase plans. Since inception of the plan through March 31, 2003, the
         Company repurchased 383,250 shares of common stock for $81,573. No
         purchases have been made under the repurchase plan since October 18,
         2002. The stock repurchase plan has been temporarily suspended.

         On May 13, 2003, the Company issued stock options for an aggregate of
         383,250 shares which vest immediately to many of its employees and to
         selected independent contractors who are sales representatives for the
         Company. The options were issued with an exercise price of $.40 per
         share based on the closing price of the Company's common stock on the
         Over-The-Counter Bulletin Board on the date of grant. The options
         terminate on the five-year anniversary of the date of grant.


                                       6
<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

INTRODUCTION
------------

Management's discussion and analysis of results of operations and financial
condition ("MD&A") is provided as a supplement to the accompanying consolidated
financial statements and footnotes to help provide an understanding of Allergy
Research Group, Inc. (the "Company") financial condition, changes in financial
condition and results of operations. The MD&A is organized as follows:

         o        CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND RISK
                  FACTORS. This section discusses how certain forward-looking
                  statements made by the Company throughout the MD&A and in the
                  consolidated financial statements are based on our present
                  expectations about future events and are inherently
                  susceptible to uncertainty and changes in circumstances.

         o        OVERVIEW. This section provides a general description of the
                  Company's business, as well as recent developments that we
                  believe are important in understanding the results of
                  operations, as well as to anticipate future trends in those
                  operations.

         o        RESULTS OF OPERATIONS. This section provides an analysis of
                  our results of operations for the second quarter 2003 compared
                  to 2002. A brief description is provided of transactions and
                  events, including related party transactions that impact the
                  comparability of the results being analyzed.

         o        LIQUIDITY AND CAPITAL RESOURCES. This section provides an
                  analysis of our financial condition and cash flows as of and
                  for the six months ended June 30, 2003.

         o        CRITICAL ACCOUNTING POLICIES. This section provides an
                  analysis of the significant estimates and judgments that
                  affect the reported amounts of assets, liabilities, revenues
                  and expenses, and related disclosure of contingent assets and
                  liabilities.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS AND RISK FACTORS
--------------------------------------------------------------

The following discussion should be read in conjunction with the Company's
financial statements and the notes thereto and the other financial information
appearing elsewhere in this document. In addition to historical information, the
following discussion and other parts of this document contain certain
forward-looking information. When used in this discussion, the words "believes,"
"anticipates," "expects," and similar expressions are intended to identify
forward-looking statements. Such statements are subject to certain risks and
uncertainties, which could cause actual results to differ materially from those
projected due to a number of factors beyond our control. The Company does not
undertake to publicly update or revise any of its forward-looking statements
even if experience or future changes show that the indicated results or events
will not be realized. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. You are also
urged to carefully review and consider our discussions regarding the various
factors, which affect our business, included in this section and elsewhere in
this report.

Factors that might cause actual results, performance or achievements to differ
materially from those projected or implied in such forward-looking statements
include, among other things: (i) the impact of competitive products; (ii)
changes in law and regulations; (iii) adequacy and availability of insurance
coverage; (iv) limitations on future financing; (v) increases in the cost of
borrowings and unavailability of debt or equity capital; (vi) the effect of
adverse publicity regarding nutritional supplements; (vii) the inability of the
Company to gain and/or hold market share; (viii) exposure to and expense of


                                       7
<PAGE>

resolving and defending product liability claims and other litigation; (ix)
consumer acceptance of the Company's products; (x) managing and maintaining
growth; (xi) customer demands; (xii) market and industry conditions including
pricing, demand for products, levels of trade inventories and raw materials
availability; (xiii) the success of product development and new product
introductions into the marketplace; (xiv) slow or negative growth in the
nutritional supplement industry; (xv) the departure of key members of
management; (xvi) the ability of the Company to efficiently manufacture its
products; as well as other risks and uncertainties that are described from time
to time in the Company's filings with the Securities and Exchange Commission.

OVERVIEW
--------

BUSINESS DESCRIPTION. Allergy Research Group, Inc. (SYMBOL: ALRG) (the "Company"
or "ARG"), through its wholly owned subsidiary, Nutricology, Inc., strives to be
an innovative leader in nutraceutical research and product formulation. Our
shares are traded on the Over The Counter Bulletin Board. Since 1980, the
Company has produced quality, hypoallergenic nutritional supplements and
supplies products to physicians and health care practitioners worldwide. These
professionals recognize the Company for the quality, purity and efficacy of its
targeted nutritional supplement line. Currently, we supply products to
approximately 4,000 physicians and health care practitioners, including accounts
in the United States, Japan, Taiwan, the United Kingdom, South Korea, Jamaica,
New Zealand, Mexico, Turkey, Norway, Sweden, Switzerland, Italy, Ireland,
Philippines, Russia, South Africa and Singapore. We develop, contract
manufacture, market and sell branded and private label products, including
vitamins and nutritional supplements, throughout the world under the
NutriCology(R) and Allergy Research Group(R) labels. Our products are
distributed through distributors, medical and professional accounts, retailers,
and consumers. We offer a line of approximately 200 products under two brands,
including vitamins in both multivitamin and single-entity formulas, minerals,
and herbals. Our products are manufactured in various forms, including capsules,
tablets, softgels, powders (drink mixes), liquids and creams. Our principal
executive offices are located at 30806 Santana Street, Hayward, California 94544
and the telephone number is (800) 545-9960.

FUTURE OPERATIONS. The success of our future operations will depend to a great
extent on the operations, financial condition, and management of the Company. We
intend to expand our position in the vitamin and nutritional supplements
markets. Specifically, our strategy continues to be to: (i) develop new brands
and product line extensions, as well as new products, through our commitment to
research and development; (ii) continue the growth of our balanced distribution
network; (iii) build our execution skills through new operations processes and
decision support systems; (iv) achieve cost superiority through formal
productivity benchmarking and continuous improvement programs; and (v) improve
our e-commerce platform. We believe that our history and reputation in the
field, multiple distribution channels, broad portfolio of products and packaging
and distribution capabilities position the Company to be a long-term competitor
in the vitamin and nutritional supplements industries.

We continue to work with Dr. Hoang on his proprietary herbal formulas with a
view to developing additional research that can be marketed to the
pharmaceutical and nutraceutical industries. This process is limited to
literature work, including patent submissions for potential products. The
research can be marketed to pharmaceutical companies either through direct sell
of the research to the pharmaceutical company, or through a joint venture
arrangement between the pharmaceutical company and the Company whereby the
parties will jointly own the patent and continue development of the products. It
is our hope that, during the process of research into possible pharmaceutical
and nutraceutical products, we will test new herbal products, or additional uses
for existing herbal products, that can be added to our current line of products
as health food or dietary supplements.

PRODUCT DEVELOPMENT. In addition to our work in the pharmaceutical and
nutraceutical fields of research, we continue to add new products to our
existing product line. During the latter part of 2002 and through the date of
this filing, the Company has added the following new products to its existing
product line: AndroBalance Androstenedione Cream (may enhance hormonal balance


                                       8
<PAGE>

in men), Progestex Natural Progesterone Cream (natural progesterone cream),
Progestex Plus Progesterone Cream with Phytoestrogens (same pure formulation of
natural progesterone as Progestex with weak estrogenic phytochemicals added that
can help regulate and support estrogenic function), Hepagenesis (Ayurvedic herb
Eclipta alba used to support the liver), Liver Saver (contains three herbs from
traditional Chinese Medicine), Phytostatin (immune support), Artemininin Gel
(supports normalization of topical conditions), Bindweed Extract (concentrated
extract of the herb CONVOLVULUS ARVENSIS), and PhytoArtemisinin (contains pure
artemisinin, QINGHAOSU, enhanced with phytosaponins.) These statements have not
been evaluated by the Food and Drug Administration. The products are not
intended to diagnose, treat, cure, or prevent any disease.

We believe that the Company has good relations with all of its current
manufacturers and suppliers. During 2002 and during the six-month period ending
June 30, 2003, we experienced a concentration of approximately 54% of our
manufacturing with four separate vendors. We do not currently have written
contracts with any of our manufacturers, but rely on long-term personal and
professional relationships with our four largest vendors. However, we believe
that, due to the large number of businesses performing this type of service in
the industry, the Company would have little difficulty in finding viable
alternatives in the event any one of these vendors became unable or determined
not to continue manufacturing our products.

RESULTS OF OPERATIONS
---------------------

Please refer to the consolidated financial statements, which are a part of this
report, for further information regarding the results of operations of the
Company.

              PERIOD ENDED JUNE 30, 2003 COMPARED TO JUNE 30, 2002
              ----------------------------------------------------

REVENUES. We had net sales of $3,447,130 for the second quarter and $6,895,892
for the six months ended June 30, 2003, compared with $3,234,125 and $6,240,312
for the same periods in 2002. The increase of $213,005, or 7%, in the second
quarter is due to increased sales to our distributors and increased demand at
retail for current and new products. The increase of $655,580, or 11%, for the
six-month period also reflects the increased demand. Average monthly sales have
increased from approximately $1,000,000 per month in 2002 to approximately
$1,100,000 in 2003.

COSTS OF SALES. Cost of sales decreased $43,653 to $1,990,480 for the three
months ended June 30, 2003, compared to $2,034,133 for the three months ended
June 30, 2002. The decrease in cost of sales is a result of higher margins
associated with retail sales, reduced freight costs due to the renegotiation of
our contract with our carrier, reduced royalties due to contract expiration and
a reduction in shipping supplies. For the six months ended June 30, 2003 cost of
sales increased $111,977 from $3,833,343 in 2002 to $3,945,320 in 2003. This
increase corresponds with the increase in sales with offsets realized in the
second quarter. Gross profit margins increased approximately 5.2% for the second
quarter and 4.2% year to date, approximating 42.8% for 2003 as a result of
higher margins associated with retail sales. There is the possibility that the
increase in gross profit may not be sustained throughout the year due to price
adjustments that may be necessary to respond to pricing pressures from our
competitors.

OPERATING EXPENSES. Total operating expenses were $990,081 for the second
quarter and $1,934,393 for six months ended June 30, 2003, compared with
$968,384 and $1,909,202 for the same periods in 2002, an increase of $21,697 and
$25,191, respectively. The increase was primarily due to the following
circumstances: (1) an increase in rent expense resulting from the loss of
sublease income associated with excess warehouse space (our lease was
renegotiated effective June 1, 2003 and the excess warehouse space was
eliminated); (2) an increase in liability insurance; (3) an increase in credit
card fees; and (4) an increase in legal fees associated with the proceedings to
collect a judgment obtained in NutriSupplies, Inc. lawsuit discussed in previous
filings. These increases were offset by: (1) a reduction in telephone expense
associated with obtaining a new contract for services; (2) a decrease in
depreciation expense; and (3) reduced expense associated with bad debt.

                                       9
<PAGE>

INTEREST EXPENSE. Interest expense was $375 for the second quarter and $1,095
for six months ended June 30, 2003 compared to $9,936 and $21,917, respectively,
for the same periods in 2003. The decrease is a result of paying down the line
of credit from $570,064 at December 31, 2001 to zero at June 30, 2003.

PROVISION FOR INCOME TAXES. As of June 30, 2003, the Company recorded a deferred
tax asset of $404,085 to be realized as a result of future taxable income offset
by net operating loss carryforwards. As of fiscal year ended December 31, 2002,
we have approximately $2,200,000 and $1,400,000, respectively, available in
federal and state net operating loss carryforwards to offset future taxable
income, which expire principally in the year 2021 (federal) and 2013 (state).
For taxable years beginning in 2002 and 2003, the State of California has
suspended the net operating loss carryover deduction for two years for losses
incurred before January 1, 2002, and for one year for losses incurred after
January 1, 2002. As a result, income taxes payable at June 30, 2003, represent
estimated 2003 California taxes based on income.

NET INCOME. During the quarter and six-month period ended June 30, 2003, we
recorded net income of $427,448 and $929,715, respectively, compared to net
income of $221,693 and $514,648 for the same periods in 2002. The increase of
$205,755 for the quarter and $415,067 for year-to-date is a result of the
increase in sales and higher profit margins.

EARNINGS PER SHARE. Earnings per share have increased to $0.03 per share for the
quarter ended June 30, 2003 from $0.01 per share for the same period in 2002.
For the six-months ended June 30, earnings per share was $0.06 in 2003 and $0.03
in 2002.

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

Current Financial Condition

During the six-month period ended June 30, 2003, the Company increased its
working capital by approximately $1,065,571 to $2,938,786 compared to a working
capital at December 31, 2002 of $1,873,215. The Company reduced outstanding
current liabilities by approximately $234,000 through cash flows available from
operating activities. The Company continues to finance its inventory and
accounts receivable through its income from operations and did not require the
use of its line of credit during the period then ended. Management believes that
the Company's operating cash flow, cash and equivalents, and borrowing capacity
under committed bank credit agreements is sufficient to fund its capital and
liquidity needs for the next twelve months.

Cash Flows

OPERATING ACTIVITIES. Net cash flow provided by operating activities was
$597,246 for the six months ended June 30, 2003. This was primarily the result
of net income of $929,715, increased by depreciation expense of $83,592 and a
decreased by inventory of $58,536. These figures were offset by an increase in
accounts receivable of $158,529, an increase in prepaid expenses and other
assets of $115,799, a decrease of accounts payable and accrued liabilities of
$183,551, and a decrease in income taxes payable of $16,718. Net cash flow
provided by operating activities for the six months ended June 30, 2002 was
$387,315, due to net income of $514,648, increased predominately by depreciation
of $110,311 and a decrease in inventory of $103,704. Offsetting these amounts
was an increase in accounts receivable of $226,250, a decrease in accounts
payable and accrued liabilities of $101,858, and an increase in deferred tax
assets of $36,000.

INVESTING ACTIVITIES. Net cash flow provided by investing activities was $52,724
for the six months ended June 30, 2003, representing repayments of loans to
officers of $58,129 offset by the acquisition of property and equipment for
$5,405. Net cash flows used in investing activities as of June 30, 2002 was
$15,693 representing the acquisition of property and equipment for $12,121 and
advances to officers of $3,572 (representing accrued interest on outstanding
loans only).

                                       10
<PAGE>

FINANCING ACTIVITIES. Net cash flow used in financing activities was $33,917 for
the six months ended June 30, 2003, representing repayments of capital lease
obligations. For the same period ended June 30, 2002, net cash flows used in
financing activities was $344,059, representing repayments on the line of credit
and capital lease obligations of $329,759 and $14,300 for the purchase of
treasury shares.

COMMON STOCK REPURCHASE PROGRAM. On May 3, 2002, the Company announced a stock
repurchase plan, whereby the Company may repurchase between 1,000,000 and
2,500,000 shares of the Company's common stock in open market transactions, from
time to time during the succeeding two years in compliance with Rule 10b-18 of
the Securities Exchange Act of 1934 and all other applicable securities
regulations. Repurchases of common shares in the open market will provide shares
for issuance to employees under stock option and stock purchase plans. Since the
inception of the plan and as of the date of this filing, the Company repurchased
383,250 shares of common stock for $81,573 all of which are currently being
reserved for issuance upon exercise of stock options granted to employees on May
12, 2003 at the then market rate of $0.40 per share under the Company's
registration statement on Form S-8. No shares have been purchased under the
repurchase plan since October 18, 2002. The stock repurchase plan has been
temporarily suspended. The Board of Directors of the Company will continue to
consider the benefits of the plan and may reinstitute it in the future.

CONCENTRATION OF CREDIT RISK. Approximately 11% of our total sales in 2002 were
attributable to a single distributor. In 2003, this distributor continued to
account for over 10% of sales. In the event we were to lose that account, we
anticipate that we would be able to convert the business to sales directly to
the customers of that distributor. As converted sales would be at a higher
margin, we do not believe the loss of the account would have a material negative
impact on sales.

CONTRACTUAL OBLIGATIONS. The Company's Contractual Obligations and Commercial
Commitments are detailed below:

<TABLE>
<CAPTION>
                        -------------------------------------------------------------------------------------
                                                 Payments Due by Period
                        -------------------------------------------------------------------------------------
                                                 Less
     Contractual                                Than 1               1-3             4 - 5        After 5
     Obligations              Total              Year               Years            Years         Years
----------------------- ------------------ ------------------ ------------------ -------------- -------------
<S>                              <C>                <C>                 <C>          <C>           <C>
Line of Credit (1)
----------------------- ------------------ ------------------ ------------------ -------------- -------------
Capital Lease
Obligations                       $14,854            $14,854
----------------------- ------------------ ------------------ ------------------ -------------- -------------

Operating Leases                 $302,643           $289,563            $13,080
----------------------- ------------------ ------------------ ------------------ -------------- -------------
Total Cash
Contractual
Obligations                      $317,497           $304,417            $13,080
----------------------- ------------------ ------------------ ------------------ -------------- -------------
</TABLE>

         (1)      This represents the Company's borrowings under its line of
                  credit with Merrill Lynch. The Merrill Lynch line of credit
                  was activated on August 19, 2002 and provides for maximum
                  financing of $500,000, bearing interest at the London
                  Interbank Offered Rate (LIBOR) plus 3.15%, computed on a
                  monthly basis. As of June 30, 2003, the interest rate on the
                  line of credit was 4.27% per annum. Interest is due monthly;
                  however, the line has not been utilized throughout the first
                  half of the year, thus no interest was due. Because the line
                  of credit is secured by substantially all of the assets of the
                  Company, if the Company were to fall into default under the
                  terms of our agreement with Merrill Lynch it could have a
                  material adverse impact on our business and financial
                  position. The officers of the Company have personally
                  guaranteed the line of credit.

                                       11
<PAGE>

RELATED PARTY TRANSACTIONS. In 1999, Dr. Stephen A. Levine, CEO, and his wife,
Susan Levine, formed Inventive Biomedical, LLC, a California limited liability
company ("IBM"), as a research and development firm. For the year ended December
31, 2001, the Company paid approximately $9,000 to IBM for research and
development and for market testing of new products. As of June 30, 2003, IBM
owes Allergy Research Group approximately $13,125. All of this debt was incurred
before July 30, 2002.

When our stock repurchase plan was announced on May 3, 2002, Dr. Levine and
Susan Levine announced that they would also be repurchasing up to 1,000,000
shares under Rule 10b-18. Since the inception of the plan, the Levines have
purchased 383,250 shares of common stock at prices ranging from $.16 to $.28 per
share on the open market. The Levines have made no purchases of the Company's
common stock since October 18, 2002.

LIQUIDITY RESOURCES. Our future funding requirements will depend on numerous
factors, some of which are beyond our control. These factors include our ability
to operate profitably, our ability to recruit and train management and
personnel, and our ability to compete with other, better capitalized and more
established competitors who offer alternative or similar products to those of
the Company. We believe that, given our positive working capital position, we
can satisfy our cash requirements over the next twelve months from operations if
we continue to operate at a profit. Our capital resources and liquidity are
expected to be provided by our cash flow from operations. In addition, we have
available federal net operating loss carryforwards of approximately $2,200,000
to offset future taxable income, which will allow our net income from operations
to be generated with potentially little or no federal income tax consequences
until the loss carryforwards are utilized.

The Company expects to continue to purchase equipment and hire new employees as
is commensurate with the growth of the business. In addition, we will continue
to invest time and effort in research for product development. We know of no
trends that are expected to affect the cost of labor or materials, and sales are
expected to be stable over the next twelve months.

CRITICAL ACCOUNTING POLICIES
----------------------------

Our discussion and analysis or plan of operations are based upon our
consolidated financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America. The
preparation of these financial statements requires us to make estimates and
judgments that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosure of contingent assets and liabilities. On an
on-going basis, we evaluate our estimates, including those related to bad debts,
inventories, intangible assets, income taxes and contingencies. We base our
estimates on historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from
these estimates under different assumptions or conditions.

We believe the following critical accounting policies reflect our more
significant estimates and assumptions used in the preparation of our
consolidated financial statements:

Income Taxes

SFAS 109, Accounting for Income Taxes, establishes financial accounting and
reporting standards for the effect of income taxes. The objectives of accounting
for income taxes are to recognize the amount of taxes payable or refundable for
the current year and deferred tax liabilities and assets for the future tax
consequences of events that have been recognized in an entity's financial
statements or tax returns. Judgment is required in assessing the future tax
consequences of events that have been recognized in our financial statements or


                                       12
<PAGE>

tax returns. Fluctuations in the actual outcome of these future tax consequences
could materially impact our financial position or our results of operations. Our
deferred tax asset on the consolidated balance sheet is recognized primarily as
a result of net operating loss carryforwards. If we did not generate any taxable
income within the next year, the asset would be overstated. We record a
valuation allowance to reduce our deferred tax assets to the amount that is more
likely than not to be realized. We have considered future market growth,
forecasted earnings, and future taxable income in determining the need for a
valuation allowance. In the event we were to determine that we would not be able
to realize all or part of our net deferred tax assets in the future, an
adjustment to the deferred tax assets would be charged to earnings in the period
such determination is made. Likewise, if we later determine that it is more
likely than not that the net deferred tax assets would be realized, the
previously provided valuation allowance would be reversed. This asset represents
approximately 9.47% of total assets at June 30, 2003. Based on our operating
results for the prior two years, and the current interim period, we believe our
estimate of deferred tax assets to be reasonable.

Allowance For Doubtful Accounts

We evaluate the collectibility of our trade receivables based on a combination
of factors. We regularly analyze our significant customer accounts, and, when we
become aware of a specific customer's inability to meet its financial
obligations to us, such as in the case of bankruptcy filings or deterioration in
the customer's operating results or financial position, we record a specific
reserve for bad debt to reduce the related receivable to the amount we
reasonably believe is collectible. The allowances are calculated based on
detailed review of certain individual customer accounts, historical rates and an
estimation of the overall economic conditions affecting our customer base. We
review a customer's credit history before extending credit. If the financial
condition of our customers were to deteriorate, resulting in an impairment of
their ability to make payments, additional allowances may be required.

Inventory

Our inventory purchases and commitments are made in order to build inventory to
meet future shipment schedules based on forecasted demand for our products. We
perform a detailed assessment of inventory for each period, which includes a
review of, among other factors, demand requirements, product life cycle and
development plans, component cost trends, product pricing and quality issues.
Based on this analysis, we record adjustments to inventory for excess,
obsolescence or impairment, when appropriate, to reflect inventory at net
realizable value. Revisions to our inventory adjustments may be required if
actual demand, component costs or product life cycles differ from our estimates.

RECENT ACCOUNTING PRONOUNCEMENTS
--------------------------------

In January 2003, the Financial Accounting Standards Board ("FASB") issued
Interpretation No. 46 "Consolidation of Variable Interest Entities, an
Interpretation of ARB No. 51" (FIN 46). FIN 46 requires certain variable
interest entities to be consolidated by the primary beneficiary of the entity if
the equity investors in the entity do not have the characteristics of a
controlling financial interest or do not have sufficient equity at risk for the
entity to finance its activities without additional subordinated financial
support from other parties. FIN 46 is effective for all new variable interest
entities created or acquired after January 31, 2003. For variable interest
entities created or acquired prior to February 1, 2003, the provisions of FIN 46
must be applied for the first interim or annual period beginning after June 15,
2003. We do not anticipate that FIN 46 will have any effect on the Company.

In April 2003, the FASB issued SFAS No. 149, "Accounting for Amendment of
Statement 133 on Derivative Instruments and Hedging Activities," which amends
and clarifies financial accounting and reporting for derivative instruments,
including certain derivative instruments embedded in other contracts and for
hedging activities under FASB Statement No. 133, Accounting for Derivative
Instruments and Hedging Activities. This Statement is generally effective for
contracts entered into or modified after June 30, 2003, and all provisions
should be applied prospectively. This statement does not affect the Company.

                                       13
<PAGE>

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial
Instruments with Characteristics of both Liabilities and Equity," which
establishes standards for how an issuer classifies and measures certain
financial instruments with characteristics of both liabilities and equity. It
requires that an issuer classify a financial instrument that is within its scope
as a liability (or an asset in some circumstances). This Statement is effective
for financial instruments entered into or modified after May 31, 2003, and
otherwise is effective at the beginning of the first interim period beginning
after June 15, 2003. It is to be implemented by reporting the cumulative effect
of a change in an accounting principle for financial instruments created before
the issuance date of the Statement and still existing at the beginning of the
interim period of adoption. Restatement is not permitted. This statement does
not affect the Company.

ITEM 3. CONTROLS AND PROCEDURES

The chief executive officer and the chief financial officer of the Registrant
has concluded based on his evaluation as of a date within 90 days prior to the
date of the filing of this Report, that the Registrant's disclosure controls and
procedures are effective to ensure that information required to be disclosed by
the Registrant in the reports filed or submitted by it under the Securities Act
of 1934, as amended, is recorded, processed, summarized and reported within the
time periods specified in the Securities and Exchange Commission's rules and
forms, and include controls and procedures designed to ensure that information
required to be disclosed by the Registrant in such reports is accumulated and
communicated to the Registrant's management, including the president, as
appropriate to allow timely decisions regarding required disclosure.

There were no significant changes in the Company's internal controls or in other
factors that could significantly affect these controls subsequent to the date of
such evaluation.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

         Not Applicable.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

         On May 13, 2003, the Company issued stock options for 383,250 shares,
which vest immediately, to many of its employees and to selected independent
contractors who are sales representatives for the Company. The options were
issued with an exercise price of $.40 per share based on the closing price of
the Company's common stock on the Over-The-Counter Bulletin Board on the date of
grant. The options terminate on the five-year anniversary of the date of grant.
As of the date of this filing, no options have been exercised.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

         Not Applicable.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         Not Applicable.

Item 5. OTHER INFORMATION

         On August 12, 2003, Manfred (Fred) Salomon was appointed President of
the Company. Mr. Salomon was hired in 2002 to fill the role of Director of
Operations. Mr. Salomon brings 40 years of executive management experience. He
comes from the home-sewing and craft industry where he managed and grew several


                                       14
<PAGE>

businesses. He also founded his own company, which he sold to the McCall Pattern
Company, where he served as Chief Operating Officer of their national
distribution company, NMI, Inc. For the last 20 years, Mr. Salomon was general
manager of Lion Notions, Inc. and Fantasy Importers, Inc., both privately held
corporations.

Item 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

3.1  Registrant's Articles of Incorporation*
3.2  Registrant's Articles of Amendment to Articles of Incorporation dated
     January 15, 1998*
3.3  Registrant's Bylaws*
4.1  Form of Common Stock Certificate*
4.2  Form of Non-Qualified Stock Option*
4.3  Form of Incentive Stock Option*
4.4  Form of Common Stock Purchase Warrant*
4.5  1998 Stock Option Plan*
10.1 License Agreement between Registrant and Jim Cassidy dated March 21, 2000*
10.2 Option Agreement between Registrant, Dr. Ba Hoang and PhytoPharm PLC*#
10.3 Loan and Security Agreement between Registrant and Aerofund Financial,
     Inc.*
10.4 Code of Business Conduct and Ethics**
99.1 Haight-Ashbury Free Medical Clinic Design Research Survey*
99.2 Certificate of Stephen A. Levine Pursuant to Section 1350 of Chapter 63 of
     Title 18 U.S. Code

* Incorporated by reference to the corresponding Exhibit previously filed as an
Exhibit to Registrant's Form 10-SB (File #0-27227).
** Incorporated by reference to the corresponding Exhibit previously filed as an
exhibit to Registrant's Form 10-KSB on March 31, 2003.
# Registrant requested confidential treatment pursuant to Rule 406 for a portion
of the referenced exhibit and separately filed such exhibit with the Commission
in conjunction with the filing of its registration statement on Form 10-SB.

    (b) Reports on Form 8-K
         None


                                       15
<PAGE>


                          ALLERGY RESEARCH GROUP, INC.
                                    SIGNATURE

           Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                                   ALLERGY RESEARCH GROUP, INC.
                                                   Registrant



Dated:  August 14, 2003
                                                   By: /s/ Stephen A. Levine
                                                       -------------------------
                                                     Chief Executive Officer and
                                                     Chief Financial Officer


                                       16
<PAGE>


                          ALLERGY RESEARCH GROUP, INC.
                              a Florida corporation
                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                           AND CHIEF FINANCIAL OFFICER


I, Stephen A. Levine, certify that:

     1.   I have reviewed this quarterly report on Form 10QSB of Allergy
          Research Group, Inc.;
     2.   Based on my knowledge, this quarterly report does not contain any
          untrue statement of a material fact or omit to state a material fact
          necessary to make the statements made, in light of the circumstances
          under which such statements were made, not misleading with respect to
          the period covered by this quarterly report;
     3.   Based on my knowledge, the financial statements, and other financial
          information included in this quarterly report, fairly present in all
          material respects the financial condition, results of operations and
          cash flows of the registrant as of, and for, the periods presented in
          this quarterly report;
     4.   The registrant's other certifying officers and I are responsible for
          establishing and maintaining disclosure controls and procedures (as
          defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant
          and have:
                  a) designed such disclosure controls and procedures to ensure
                     that material information relating to the registrant,
                     including its consolidated subsidiaries, is made known to
                     us by others within those entities, particularly during the
                     period in which this quarterly report is being prepared;
                  b) evaluated the effectiveness of the registrant's disclosure
                     controls and procedures as of a date within 90 days prior
                     to the filing date of this quarterly report (the
                     "Evaluation Date"); and
                  c)  presented in this quarterly report our conclusions
                      about the effectiveness of the disclosure controls and
                      procedures based on our evaluation as of the Evaluation
                      Date;
     5.   The registrant's other certifying officers and I have disclosed, based
          on our most recent evaluation, to the registrant's auditors and the
          audit committee of registrant's board of directors (or persons
          performing the equivalent functions):
                  a) all significant deficiencies in the design or operation of
                     internal controls which could adversely affect the
                     registrant's ability to record, process, summarize and
                     report financial data and have identified for the
                     registrant's auditors any material weaknesses in internal
                     controls; and
                  b)  any fraud, whether or not material, that involves
                      management or other employees who have a significant
                      role in the registrant's internal controls; and

     6.   The registrant's other certifying officers and I have indicated in
          this quarterly report whether there were significant changes in
          internal controls or in other factors that could significantly affect
          internal controls subsequent to the date of our most recent
          evaluation, including any corrective actions with regard to
          significant deficiencies and material weaknesses.

Date: August 14, 2003


/s/ Stephen A. Levine
---------------------

Stephen A. Levine


Chief Executive Officer and Chief Financial Officer


                                       17